CE2 HEALTH ECONOMIC ASSESSMENT OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
Abstract
Authors
L Annemans K Moeremans H Lamarque